These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 38244446)

  • 1. Baseline absolute monocyte count predicts lung function decline among patients with systemic sclerosis-associated interstitial lung disease: A post hoc analysis from the focuSSced trial.
    Bernstein EJ; Denton CP; Huang S; Khanna D
    Semin Arthritis Rheum; 2024 Apr; 65():152376. PubMed ID: 38244446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic and predictive markers of systemic sclerosis-associated interstitial lung disease in a clinical trial and long-term observational cohort.
    Ghuman A; Khanna D; Lin CJF; Furst DE; Raghu G; Martinez FJ; Zucchetto M; Huang S; Jennings A; Nihtyanova SI; Denton CP
    Rheumatology (Oxford); 2024 Feb; 63(2):472-481. PubMed ID: 37228011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.
    Highland KB; Distler O; Kuwana M; Allanore Y; Assassi S; Azuma A; Bourdin A; Denton CP; Distler JHW; Hoffmann-Vold AM; Khanna D; Mayes MD; Raghu G; Vonk MC; Gahlemann M; Clerisme-Beaty E; Girard M; Stowasser S; Zoz D; Maher TM;
    Lancet Respir Med; 2021 Jan; 9(1):96-106. PubMed ID: 33412120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial.
    Khanna D; Lin CJF; Furst DE; Wagner B; Zucchetto M; Raghu G; Martinez FJ; Goldin J; Siegel J; Denton CP
    Am J Respir Crit Care Med; 2022 Mar; 205(6):674-684. PubMed ID: 34851799
    [No Abstract]   [Full Text] [Related]  

  • 5. Cohort Enrichment Strategies for Progressive Interstitial Lung Disease in Systemic Sclerosis From European Scleroderma Trials and Research.
    Hoffmann-Vold AM; Brunborg C; Airò P; Ananyeva LP; Czirják L; Guiducci S; Hachulla E; Li M; Mihai C; Riemekasten G; Sfikakis PP; Valentini G; Kowal-Bielecka O; Allanore Y; Distler O;
    Chest; 2023 Mar; 163(3):586-598. PubMed ID: 36244404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tocilizumab in Patients with Systemic Sclerosis-associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis.
    Ghazipura M; Macrea M; Herman D; Barnes H; Knight SL; Silver RM; Montesi SB; Raghu G; Hossain T
    Ann Am Thorac Soc; 2024 Feb; 21(2):328-337. PubMed ID: 37773003
    [No Abstract]   [Full Text] [Related]  

  • 7. Impact of lung function decline on time to hospitalisation events in systemic sclerosis-associated interstitial lung disease (SSc-ILD): a joint model analysis.
    Kreuter M; Del Galdo F; Miede C; Khanna D; Wuyts WA; Hummers LK; Alves M; Schoof N; Stock C; Allanore Y
    Arthritis Res Ther; 2022 Jan; 24(1):19. PubMed ID: 35012623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KL-6 But Not CCL-18 Is a Predictor of Early Progression in Systemic Sclerosis-related Interstitial Lung Disease.
    Salazar GA; Kuwana M; Wu M; Estrada-Y-Martin RM; Ying J; Charles J; Mayes MD; Assassi S
    J Rheumatol; 2018 Aug; 45(8):1153-1158. PubMed ID: 29961690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclophosphamide for connective tissue disease-associated interstitial lung disease.
    Barnes H; Holland AE; Westall GP; Goh NS; Glaspole IN
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD010908. PubMed ID: 29297205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does Systemic Sclerosis-associated Interstitial Lung Disease Burn Out? Specific Phenotypes of Disease Progression.
    Guler SA; Winstone TA; Murphy D; Hague C; Soon J; Sulaiman N; Li KH; Dunne J; Wilcox PG; Ryerson CJ
    Ann Am Thorac Soc; 2018 Dec; 15(12):1427-1433. PubMed ID: 30188737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tocilizumab Prevents Progression of Early Systemic Sclerosis-Associated Interstitial Lung Disease.
    Roofeh D; Lin CJF; Goldin J; Kim GH; Furst DE; Denton CP; Huang S; Khanna D;
    Arthritis Rheumatol; 2021 Jul; 73(7):1301-1310. PubMed ID: 33538094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease.
    Volkmann ER; Tashkin DP; Roth MD; Clements PJ; Khanna D; Furst DE; Mayes M; Charles J; Tseng CH; Elashoff RM; Assassi S
    Arthritis Res Ther; 2016 Dec; 18(1):305. PubMed ID: 28038680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.
    Khanna D; Lin CJF; Furst DE; Goldin J; Kim G; Kuwana M; Allanore Y; Matucci-Cerinic M; Distler O; Shima Y; van Laar JM; Spotswood H; Wagner B; Siegel J; Jahreis A; Denton CP;
    Lancet Respir Med; 2020 Oct; 8(10):963-974. PubMed ID: 32866440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decline in forced vital capacity in subjects with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial compared with healthy reference subjects.
    Maher TM; Bourdin A; Volkmann ER; Vettori S; Distler JHW; Alves M; Stock C; Distler O
    Respir Res; 2022 Jul; 23(1):178. PubMed ID: 35790961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of lung function and baseline clinical characteristics on patient-reported outcome measures in systemic sclerosis-associated interstitial lung disease.
    Kreuter M; Hoffmann-Vold AM; Matucci-Cerinic M; Saketkoo LA; Highland KB; Wilson H; Alves M; Erhardt E; Schoof N; Maher TM
    Rheumatology (Oxford); 2023 Feb; 62(SI):SI43-SI53. PubMed ID: 35640959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database.
    Hoffmann-Vold AM; Allanore Y; Alves M; Brunborg C; Airó P; Ananieva LP; Czirják L; Guiducci S; Hachulla E; Li M; Mihai C; Riemekasten G; Sfikakis PP; Kowal-Bielecka O; Riccardi A; Distler O;
    Ann Rheum Dis; 2021 Feb; 80(2):219-227. PubMed ID: 32988845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KL6 and IL-18 levels are negatively correlated with respiratory function tests and ILD extent assessed on HRCT in patients with systemic sclerosis-related interstitial lung disease (SSc-ILD).
    Sieiro Santos C; Antolín SC; Lorenzo JC; Garay CL; Morales CM; de Miguel EB; Guerrero MR; Herránz LS; Álvarez ED
    Semin Arthritis Rheum; 2024 Apr; 65():152366. PubMed ID: 38290372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of progression in systemic sclerosis patients with interstitial lung disease.
    Distler O; Assassi S; Cottin V; Cutolo M; Danoff SK; Denton CP; Distler JHW; Hoffmann-Vold AM; Johnson SR; Müller Ladner U; Smith V; Volkmann ER; Maher TM
    Eur Respir J; 2020 May; 55(5):. PubMed ID: 32079645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Nintedanib on Lung Function in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Further Analyses of a Randomized, Double-Blind, Placebo-Controlled Trial.
    Maher TM; Mayes MD; Kreuter M; Volkmann ER; Aringer M; Castellvi I; Cutolo M; Stock C; Schoof N; Alves M; Raghu G;
    Arthritis Rheumatol; 2021 Apr; 73(4):671-676. PubMed ID: 33142016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nintedanib in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score.
    Kuwana M; Allanore Y; Denton CP; Distler JHW; Steen V; Khanna D; Matucci-Cerinic M; Mayes MD; Volkmann ER; Miede C; Gahlemann M; Quaresma M; Alves M; Distler O
    Arthritis Rheumatol; 2022 Mar; 74(3):518-526. PubMed ID: 34514739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.